Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome

Ann Intern Med. 1986 Apr;104(4):547-53. doi: 10.7326/0003-4819-104-4-547.

Abstract

We describe the clinical characteristics and prognostic features of 71 patients with advanced poorly differentiated carcinoma of unknown primary site. These patients had at least one component of the extragonadal germ cell cancer syndrome that we have previously described. Of 68 patients who received therapy, 62 were given intensive cisplatin-based combination chemotherapy that is used for treatment of germinal neoplasms. Fifteen patients (22%) had complete responses, and 9 patients (13%) have remained free of tumor after a minimum follow-up of 36 months (range, 36 to 67 months). Tumor in the mediastinum, retroperitoneum, and lymph nodes was associated with a favorable outcome of treatment when compared with tumor in other locations (p = 0.0016, Cox regression analysis). Although the histogenesis of tumors in many of these patients remains unclear, we believe the tumors most likely originate from germ cells. Patients with advanced poorly differentiated carcinoma should be considered for treatment with cisplatin-based combination chemotherapy, particularly if tumors occur predominantly in the mediastinum, retroperitoneum, or lymph nodes.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Actuarial Analysis
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / drug therapy
  • Carcinoma / mortality
  • Carcinoma / pathology
  • Carcinoma / secondary*
  • Cisplatin / administration & dosage
  • Female
  • Humans
  • Lymphatic Metastasis / drug therapy
  • Male
  • Mediastinal Neoplasms / drug therapy
  • Mediastinal Neoplasms / secondary
  • Microscopy, Electron
  • Middle Aged
  • Neoplasms, Germ Cell and Embryonal / drug therapy
  • Neoplasms, Germ Cell and Embryonal / secondary
  • Prognosis
  • Retroperitoneal Neoplasms / drug therapy
  • Retroperitoneal Neoplasms / secondary
  • Smoking
  • Syndrome

Substances

  • Cisplatin